German gatekeeper backs Pfizer and BMS' Eliquis; Canadian court to allow Proscar class action;

@FiercePharma: U.S. Trade Rep weighs response to India's patent smackdown, after Novartis' loss on Glivec Monday. More | Follow @FiercePharma

@EricPFierce: Lilly is installing some new technology in its US insulin cartridge plant, to pump up output. Article | Follow @EricPFierce

> Germany's tough new pricing authority determined that Bristol-Myers Squibb ($BMY) and Pfizer's ($PFE) anticoagulant Eliquis delivers a "significant" additional benefit in stroke prevention for patients 65 and over, compared with warfarin or aspirin therapy. Report

> A Canadian judge will allow men to pursue class-action claims against Merck ($MRK) over sexual side effects of its drug finasteride, sold in the prostate treatment Proscar and baldness remedy Propecia. Report

> GlaxoSmithKline ($GSK) won approval for its four-strain influenza vaccine in Germany and the U.K. Release

> PhRMA and the Generic Pharmaceuticals Association advocated a federal track-and-trace system to secure the pharmaceutical supply chain. Report

Biotech News

@FierceBiotech: Elan closes $3.25B Tysabri deal and preps for biotech deal spree. News | Follow @FierceBiotech

@JohnCFierce: AstraZeneca's latest biotech deal offers more early-stage research work. Years away from PhIII, where it needs help. More | Follow @JohnCFierce.

@RyanMFierce: Pfizer made an another early-stage deal with a Cambridge, MA biotech. This one with Gates-backed Tetragenics. Release | Follow @RyanMFierce

> AstraZeneca gambles on cardio therapy in AlphaCore buyout. Report

> Resurgent Pfizer partners with Bind on new nanotech drug effort. News

> Biotech gamblers crowd high-stakes game for Sarepta. More

Medical Device News

@FierceMedDev: Cardiac Science sells off diagnostic biz, focuses on defibrillators. News | Follow @FierceMedDev

@MarkHFierce: Folks have figured out a way to goose Dx tech that could enable personalized prostate cancer treatments. Release | Follow @MarkHFierce

 @DamianFierce: Now, per Reuters, Thermo Fisher is in the lead with a $12B bid on Life Tech. More | Follow @DamianFierce

> Hitachi wins FDA nod for new CT scanner. News

> U.K. regulators issue alert over Hoya's intraocular lens implant. Article

> Is Abbott trying to buy its way back into the drug biz? Item

Biomarkers News

 @EmilyMFierce: New prostate cancer predictors revealed. Report | Follow @EmilyMFierce

> CV biomarker study finds evidence of bias, exaggeration in the field. Story

> French researchers cast doubt on chemo biomarker's viability. Item

> Biomarkers predict risk of diabetes-related kidney trouble. Article

> U.K. team concocts rapid approach for colorectal cancer biomarker detection. More

Drug Delivery News

@MichaelGFierce: Biogen Idec's new oral MS drug Tecfidera has an unknown mechanism of action, the company says. More | Follow @MichaelGFierce

> Cholesterol 'rafts' enable cancer-killing delivery of DNA, RNA. Report

> Analysts expect nanotech drug delivery boom despite safety concerns. Story

> Pozen seeks FDA approval for layered aspirin cardiovascular treatment. Item

> FDA rejects A.P. Pharma's delayed-onset chemo drug. More

> Entrega, other startups make strides in needle-free delivery. Article

And Finally... Feeling hungry may protect the brain against Alzheimer's. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.